- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00409656
Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients
Most high risk keratoplasties are currently performed under systemic immunosuppression. Immunosuppressants are currently either Cyclosporine A or mycophenolate mofetile, administered for around 6 months. Due to potentially severe adverse effects, new immunosuppressive exerting less side effects would be desirable. Basiliximab is a monoclonal, chimeric antibody, targeted specifically against the Interleukin-2-Rezeptor from activated T-cells. This agent is known to specifically inhibit T-cell proliferation upon intravenous application only twice following transplantation. Basiliximab has already been demonstrated effective in kidney transplantation.
This investigation is a prospective, randomized clinical trial on orthotopic, high-risk penetrating keratoplasty. Basiliximab is evaluated against systemic Cyclosporine A. Primary endpoint is graft rejection. Secondary endpoint is clear graft survival.
Study Overview
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- high risk keratoplasty
Exclusion Criteria:
- normal risk keratoplasty
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Graft rejection
|
Secondary Outcome Measures
Outcome Measure |
---|
Clear graft survival
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Thomas Reinhard, MD, Prof., University Eye Hospital, Freiburg
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FR-2003-12-2005-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corneal Transplantation
-
National Taiwan University HospitalCompletedCorneal TransplantationTaiwan
-
Oregon Health and Science UniversityUniversity of California, San Francisco; Stanford UniversityActive, not recruitingKeratoplasty | Grafting, Corneal | Transplantation, Corneal | Transplantation, Cornea | Keratoplasty, LamellarUnited States
-
Sheba Medical CenterUnknownCorneal TransplantationIsrael
-
University Hospital FreiburgHoffmann-La RocheCompletedCorneal TransplantationGermany
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceCompletedCorneal TransplantationFrance
-
Ocular Systems, Inc.Wake Forest UniversityUnknown
-
University of VirginiaCompletedCorneal TransplantationUnited States
-
Vanderbilt University Medical CenterNot yet recruitingCorneal TransplantationUnited States
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityUnknownCorneal TransplantationChina
-
Lux Biosciences, Inc.TerminatedCorneal Transplantation | Corneal Graft RejectionUnited States, Germany
Clinical Trials on Basiliximab
-
Drexel University College of MedicineNovartisTerminatedEnd Stage Renal DiseaseUnited States
-
McGill University Health Centre/Research Institute...Unknown
-
Asan Medical CenterUnknownKidney TransplantationKorea, Republic of
-
Fort Worth Clinical Sciences Working GroupTCU and UNTHSC School of MedicineNot yet recruitingSARS-CoV2 Infection | Cytokine Storm | SARS-CoV-2 Acute Respiratory Disease
-
Gary Archer Ph.D.National Cancer Institute (NCI)CompletedMalignant Neoplasms BrainUnited States
-
The First Affiliated Hospital of Soochow UniversityThe Second People's Hospital of Huai'an; Soochow Hopes Hematonosis HospitalRecruitingSafety and EfficacyChina
-
University Health Network, TorontoNovartisCompletedEmphysema | COPD | Alpha-1 Antitrypsan DeficiencyCanada
-
Fuzhou General HospitalUnknownLiving-relative Kidney TransplantationChina
-
University Hospital, BrestUnknown
-
King Faisal Specialist Hospital & Research CenterRecruitingKidney TransplantationSaudi Arabia